ASCT2 has been identified as an EGFR-associated protein that can be co-targeted by cetuximab, an EGFR antibody approved for metastatic human head and neck squamous cell carcinoma treatment, sensitizing the cancer cells to ROS-induced apoptosis through reduction of intracellular levels of glutamine and, consequently, of glutathione [85]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.